ReviewFrontiers in pharmacology2023
The potential role of nanomedicine in the treatment of breast cancer to overcome the obstacles of current therapies.
Review in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Polymer-Metal Nanoparticle Hybrid Systems for Targeted Breast Cancer Therapy: Advances and Clinical Translation.Cureus · 2026Review
- Precision Nanotechnology: Revolutionizing Therapeutic Strategies Against Drug-Resistant Breast Cancer.Annals of biomedical engineering · 2026Review
- Advancements in nanobiosensors for early cancer detection, challenges, treatment, and future prospects: a comprehensive review.Discover nano · 2026Review
- Artificial Intelligence and Prostate-Breast Cancer Biology: Recent Advances in Treatments and Perspectives - A Comprehensive Review.Health science reports · 2026Article
- Nanomedicine-Based Therapeutic Approaches in Colorectal Cancer Using Patient-Derived Xenograft Models: Prospects and Challenges.International journal of nanomedicine · 2026Review
- Nanomaterials in gene therapy and genome editing: challenges and emerging directions.Journal of nanobiotechnology · 2025Review
- Polymeric Nanoparticles with Surface-Anchored Functional Groups as Chelating Agents for Calcium (CaPharmaceuticals (Basel, Switzerland) · 2025Article
- Microneedles as Gateways: Smart Nanoparticle Delivery for Enhanced Breast Cancer Treatment.ACS omega · 2025Review
- Dual Stimuli-Responsive Gemcitabine-Conjugated Alginate-Chitosan Nanoparticles for Triple-Negative Breast Cancer Therapy: A Smart Approach.Bioconjugate chemistry · 2025Article
- Recent advancements in nanomaterial-based biosensors for diagnosis of breast cancer: a comprehensive review.Cancer cell international · 2025Review
- Nanoparticles as Novel Drug Delivery Systems for Cancer Treatment: Current Status and Future Perspectives.Current pharmaceutical design · 2025Review
- Recent innovations in nanomedicine and nano-based techniques for the treatment of breast cancer.BioImpacts : BI · 2025Review
- Autophagy stimulation influenced the angiogenesis and metastasis behavior of human triple-negative breast cancer cells.BioImpacts : BI · 2025Article
- New Radiopharmaceutical Tracers in Breast Cancer Diagnosis and Therapy.Anti-cancer agents in medicinal chemistry · 2025Review
- Platinum Group Metals Nanoparticles in Breast Cancer Therapy.Pharmaceutics · 2024Review
- METTL16 regulates the mRNA stability of FBXO5 via m6A modification to facilitate the malignant behavior of breast cancer.Cancer & metabolism · 2024Article
- Self-Assembled Nanocomposite DOX/TPORPharmaceutics · 2024Article
- Antioxidant Enzymes and Their Potential Use in Breast Cancer Treatment.International journal of molecular sciences · 2024Review
- Review
- Advancements in Solid Lipid Nanoparticles and Nanostructured Lipid Carriers for Breast Cancer Therapy.Current pharmaceutical design · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer (BC) is the most frequently diagnosed malignant tumor among women in the world. BC is the heterogeneous tumor with different subtypes including luminal A-like, luminal B-like (HER2-/HER2+), HER2 enriched, and triple-negative BC. The therapeutic strategies including surgery, chemotherapy, radiotherapy, targeted therapy, and endocrine therapy are well developed and commonly used in the treatment of BC. However, some adverse effects of these conventional treatments limited their wide application in clinical. Therefore, it is necessary to develop more safe and more efficient individualized treatment strategies of the BC. Nanomedicine, as the most promising strategy for controlled and targeted drug delivery, is widely used in multiple aspects of cancer therapy. Importantly, accumulative evidences show that nanomedicine has achieved good outcomes in the treatment of BC and a huge amount of BC patients benefited from the nanomedicine related treatments. In this review, we summarized and discussed the major problems occurred during the administration of conventional treatment strategies for BC and the potential roles of nanomedicine in promoting the treatment efficacy of BC by overcoming obstacles of current treatment of BC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.